Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- J-TEC to Venture into CRO Biz for Regenerative Medicine
March 16, 2016
- Takeda Spins Out Investigational Stress Urinary Incontinence Drug to Yamada-Led US Firm
March 16, 2016
- Ethical Drug Sales Up 7.0% in January: Crecon Report
March 15, 2016
- Lilly Seeks to Block Launch of Evista Generics Approved in February
March 15, 2016
- AbbVie Launches Japan PIII Trials for All Hep C Genotypes
March 15, 2016
- MSD Files 2 Antivirals for Hep C Treatment in Japan
March 14, 2016
- Ono Beefing Up Organization for Safe Use of Opdivo, Eyes Larger Cancer Sales Force
March 11, 2016
- Mitsubishi Tanabe to Solely Market Janssen’s Simponi in Japan
March 11, 2016
- Takecab Most Heavily Pitched Drug in January: Anterio
March 11, 2016
- Re-Pricing, Z2, Deferred Price Cuts Hammering Mainstay Drugs, Otsuka Sees Double-Digit Reductions for Top 5 Sellers: Tally
March 9, 2016
- Japan Generic Market to Reach 1.1 Trillion Yen in 2018: Fuji Keizai
March 9, 2016
- Nemolizumab Shows Efficacy for Atopic Dermatitis in Global PII: Chugai
March 8, 2016
- Sandoz Suffers Hefty 20% Price Cuts in FY2016 Revision, Teva 8.3%: Jiho Survey
March 8, 2016
- Kyowa Kirin Expects to Double Sales Force in US to Build Independent Marketing System; Anticipates Launch of Parkinson’s Drug in 2018
March 8, 2016
- Toyama Chemical Sues 3 Generic Firms over Ozex Patent
March 8, 2016
- Debiopharm Wins Elplat Patent Suit against Nippon Kayaku
March 8, 2016
- Z2 Price Cut Rule to Smash Mitsubishi Tanabe, Astellas, Pfizer: Jiho Tally
March 7, 2016
- Drug Price Cut to Net Out at 5.5% for Chugai, Gilead to Suffer 31.65% in Full: Jiho Tally
March 7, 2016
- Japan NDA Filed for Anti-HIV Drug Genvoya
March 7, 2016
- NHI Price Reduction Rates for Plavix Generics to Vary Largely between 17.1% and 59.5%: Jiho Tally
March 7, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…